VentriPoint Diagnostics stock analysis
VentriPoint Diagnostics (5V7) Stock Price & Analysis
5V7 Stock Chart & Stats
- Day’s Range
- EUR 0.03 - EUR 0.03
- 52-Week Range
- EUR 0.03 - EUR 0.09
- Previous Close
- EUR 0.03
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 7.97M
- Enterprise Value
- EUR 22.72M
- Total Cash (Recent Filing)
- EUR 333.63K
- Total Debt (Recent Filing)
- EUR 2.62M
- Price to Earnings (P/E)
- ―
- Beta
- -0.52
- Next Earnings
- Dec 02, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
TTM revenue growth of 15.3% indicates that the company is expanding commercial activity and gaining adoption for its cardiac imaging software. Continued top-line growth can improve operating leverage over time, broaden the customer base, and provide a stronger foundation for future profitability.
High Gross Margin
A gross margin near 89.6% reflects attractive underlying economics for the company’s software and diagnostic analytics offering. If revenue continues to scale, the limited direct cost burden could allow a larger share of incremental sales to support development, commercialization, and eventual operating profitability.
Narrowing Losses
The meaningful reduction in losses versus 2023–2024 suggests that operating performance is moving in a better direction, even though the company remains unprofitable. Sustaining this improvement would reduce the distance to break-even and could make future revenue growth more financially productive.
Bears Say
Persistent Unprofitability
Negative net margin, EBIT, and EBITDA show that the company’s current revenue base does not yet cover its operating cost structure. Continued losses can constrain investment capacity and make the benefits of strong revenue growth dependent on further expense control or additional financing.
Negative Cash Flow
Operating and free cash flow of approximately negative $1.92 million indicate that the business is still consuming cash to fund operations rather than generating internal liquidity. Although burn has improved from prior years, ongoing cash needs may limit strategic flexibility and require continued external support.
Deteriorated Capital Structure
Negative equity and debt that exceeds the stated asset base indicate a materially stressed capital structure. The shift from positive equity in 2022–2023 to negative equity in 2024–TTM reduces financial flexibility, increases dependence on external financing, and heightens the consequences of continued losses.
VentriPoint Diagnostics News
5V7 FAQ
What was VentriPoint Diagnostics’s price range in the past 12 months?
What is VentriPoint Diagnostics’s market cap?
When is VentriPoint Diagnostics’s upcoming earnings report date?
How were VentriPoint Diagnostics’s earnings last quarter?
Is VentriPoint Diagnostics overvalued?
Does VentriPoint Diagnostics pay dividends?
What is VentriPoint Diagnostics’s EPS estimate?
How many shares outstanding does VentriPoint Diagnostics have?
What happened to VentriPoint Diagnostics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of VentriPoint Diagnostics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
VentriPoint Diagnostics
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Hugh MacNaught
- Employees
- 10
- Website
- www.ventripoint.com
- Address
- 18 Hook Avenue, Toronto, ON, M6P 1T4, CA
VentriPoint Diagnostics (5V7) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |




